Clearmind Medicine Inc.
CMND
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1M
$0.72
▼ -11.09%
P/E
—
Mkt Cap
$1.1M
52-Wk Range
$0.71–$480.00
52-Week Range
$0.71 - $480.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 99.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Early-stage positioning in emerging psychedelic medicine market
- Focused pipeline targeting underserved patient populations with high unmet medical needs
- Novel psychedelic compound development and intellectual property
- Strategic focus on FDA-tractable indications with significant commercial potential
Bear Case
1 risk
- Low volatility (beta -1.2).
Growth
No forward estimates available
Increasing regulatory acceptance and clinical validation of psychedelic therapies
Value
Valuation data unavailable
Momentum
Falling
-69.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CMND right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 10, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.57.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q3 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · Jul 30, 2026
vs Industry
How CMND stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related